Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism

AUSTIN, Texas, Feb. 28, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will present at the 2017 Keystone Symposia Conference on Tumor Metabolism: Mechanisms and Targets, taking place March 5 – 9 in Whistler, British Columbia.

Details of the presentation, which will be delivered both orally and as a poster presentation, are listed below:

Title: Therapeutic depletion of arginine via arginase I (AEB1102, Pegzilarginase) administration inhibits tumor growth and further sensitizes the tumor to immunotherapy with anti-PD1 and anti-PD-L1

Abstract Number: 1004

Session Title: Poster Session 1
Date: Monday, March 6
Presentation Time: 7:30 – 10:00 p.m.PT
Location: Whistler Conference Centre, Sea to Sky Ballroom A

Workshop Title: Workshop 2
Date: Wednesday, March 8
Presentation Time: 2:30 – 4:30 p.m. PT
Presenter: Giulia Agnello, Ph.D.
Location: Whistler Conference Centre, Sea to Sky Ballroom C

About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. For more information, please visit http://aegleabio.com.

Safe Harbor / Forward Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, the potential therapeutic benefits and economic value of our product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact: 
Kelly Boothe, Ph.D. 
Pure Communications 
415.946.1076
[email protected]

Investor Contact:
Charles N. York II 
Chief Financial Officer 
Aeglea BioTherapeutics 
[email protected]